Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide


You May Also Like

Immunomedics Announces Conference Call and Webcast for First Quarter Fiscal 2017 Results

MORRIS PLAINS, N.J., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced ...

VBL Therapeutics to Report Second Quarter 2017 Results on August 14

TEL AVIV, Israel, Aug. 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...